In this article, we will look at the 10 Best Small-Cap Stocks Ready to Explode in 2026.
On January 27, Matt Stucky from Northwestern Mutual appeared on a CNBC Television interview to discuss the performance of small-cap stocks. The Russell 2000 has outperformed the S&P 500 over the past six months, with returns of 18.31% compared to 9.53%. The outperformance is primarily driven by lower valuations of small caps and expectations of rate cuts. Stucky believes that this outperformance trend is expected to continue. He noted that this performance was long overdue, mainly because of the narrowness of the market around the big tech names.
He noted that over the past few years, higher interest rates have benefited larger companies with AI and tech taking the lead. However, now the situation is changing with easing monetary policies and investors looking to diversify their portfolios. Stucky highlighted that as the Federal Reserve continues to ease rates and small-cap stocks post upward earnings revisions, he sees significant room for small-cap stocks to run.
With that, let’s take a look at the 10 Best Small-Cap Stocks Ready to Explode in 2026.
A person with a cell phone who is looking for new stocks
Our Methodology
To curate the list of 10 Best Small Cap Stocks Ready to Explode in 2026, we used the Finviz Stock Screener, CNN, WSJ, and Insider Monkey’s Q3 2025 database. Using the screener, we aggregated a list of small-cap stocks (market cap between $300 million and $2 billion), for which analysts expect more than 50% upside. Next, we cross-checked the market cap from WSJ and the upside potential from CNN and ranked the stock in ascending order of the number of hedge fund holders. Please note that the data was recorded on January 27, 2026.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10 Best Small Cap Stocks Ready to Explode in 2026
10. SharpLink Gaming, Inc. (NASDAQ:SBET)
Market Cap: $1.96 billion
Upside: 100.00%
Number of Hedge Fund Holders: 21
SharpLink Gaming, Inc. (NASDAQ:SBET) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 12, Gautam Chhugani from Bernstein reiterated a Buy rating on the stock with a $24 price target. Earlier on January 7, Brian Kinstlinger from Alliance Global also reiterated a Buy rating on SharpLink Gaming, Inc. (NASDAQ:SBET) but lowered the price target from $48 to $20.
Analysts at Alliance Global noted that the company now holds 864,402 Ethereum, which are worth roughly $2.9 billion. The firm noted that the price of Ethereum has gone down by around 30% since the firm’s last update on the stock, and they have reduced the price target.
That said, earlier on January 5, Cantor Fitzgerald analyst Brett Knoblauch initiated SharpLink Gaming, Inc. (NASDAQ:SBET) with a Buy rating and a $15 price target. The analyst noted that the company has experienced management with significant expertise in crypto and the Ethereum ecosystem. The analyst believes that this expertise will allow the company to execute successful Ethereum deployment strategies, which will eventually grow ETH at a faster rate.
SharpLink Gaming, Inc. (NASDAQ:SBET) is an online performance-based marketing company that serves the US sports betting and global iGaming industries by driving qualified traffic, player acquisitions, retention, and conversions through its PAS.net affiliate network.
9. Innodata Inc. (NASDAQ:INOD)
Market Cap: $1.87 billion
Upside: 55.41%
Number of Hedge Fund Holders: 21
Innodata Inc. (NASDAQ:INOD) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 20, Innodata Inc. (NASDAQ:INOD) announced receiving a contract for the US Missile Defense Agency’s Scalable Homeland Innovative Enterprise Layered Defense (SHIELD) indefinite-delivery/indefinite-quantity (IDIQ) contract. Management noted that this contract enables the company to bid on future task orders related to research, development, prototyping, engineering, and more.
That said, on January 5, BWS Financial reiterated a Buy rating on the stock with a $110 price target. BWS named Innodata Inc. (NASDAQ:INOD) as one of its top picks for 2026, driven by catalysts driving revenue growth throughout the year. The firm highlighted that the company entered the fiscal Q4 2025 with a government contract. This contract is expected to boost revenue for the company by year-end 2026. The analysts from BWS noted that as the AI landscape continues to grow, the use cases for data sets are only expected to advance further.
Innodata Inc. (NASDAQ:INOD) is a New Jersey–based data engineering and AI services company that builds and operates AI and data solutions for leading global technology companies and large enterprises.
8. Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
Market Cap: $1.97 billion
Upside: 74.40%
Number of Hedge Fund Holders: 22
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 26, Sam Slutsky from LifeSci Capital reiterated a Buy rating on the stock and raised the price target from $39 to $45. Earlier, on January 14, Kelsey Goodwin from Piper Sandler reiterated a Buy rating on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) with a price target of $40.
Analysts at Piper Sandler noted that the bullish rating is based on the company’s Palazestrant. Palazestrant is a potential best-in-class for treating ER+/HER2- breast cancer. The firm highlighted the drug’s complete ER antagonism and ER degradation ability. These capabilities are expected to make the drug an upcoming treatment in the huge breast cancer market.
In addition, the firm highlighted that the company is expecting multiple phase 3 trials in 2026, which are expected to add further upside to the stock. Piper Sandler expects Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) to launch Palazestrant by next year.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is focused on the development of treatments for patients with breast cancer and other serious diseases. Its key pipeline includes Palazestrant and OP-3136.
7. Progress Software Corporation (NASDAQ:PRGS)
Market Cap: $1.75 billion
Upside: 59.09%
Number of Hedge Fund Holders: 25
Progress Software Corporation (NASDAQ:PRGS) is one of the Best Small Cap Stocks Ready to Explode in 2026. Wall Street is bullish on the stock since the company released its fiscal Q4 2025 earnings on January 20. Recently, on January 22, Fatima Boolani from Citi raised the firm’s price target on the stock from $54 to $60, with a Buy rating. Earlier, on January 21, Lucky Schreiner from D.A. Davidson also reiterated a Buy rating on Progress Software Corporation (NASDAQ:PRGS) with a $70 price target.
During the quarter, the company grew its revenue by 17.54% year-over-year to $252.67 million, but fell short of the expectations by $194,700. On the bright side, the EPS of $1.51 exceeded the consensus by $0.20. Management noted 2025 to be one of the strongest years for the company, driven by a strong execution of its strategy to invest, innovate, acquire, and integrate. Notably, the company reached an ARR of $852 million, reflecting a 2% increase year-over-year.
Analysts at D.A. Davidson noted that the company has achieved a healthy annual recurring revenue and SaaS revenue. The firm believes that the company is set to benefit from customers seeking to adopt new AI capabilities.
Progress Software Corporation (NASDAQ:PRGS) provides products and solutions that develop and deploy mission-critical business applications, including Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, and more.
6. Immunocore Holdings plc (NASDAQ:IMCR)
Market Cap: $1.77 billion
Upside: 85.13%
Number of Hedge Fund Holders: 25
Immunocore Holdings plc (NASDAQ:IMCR) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $100 price target. Earlier, on January 6, UBS also initiated Immunocore Holdings plc (NASDAQ:IMCR) with a Buy rating and a $55 price target.
Analysts at UBS see significant potential upside for the stock because it is currently trading close to the value of its approved drug Kimmtrak. The firm noted that this means that the market has assigned almost no value to two of the company’s upcoming phase 3 trials. UBS believes that these trials could act as catalysts for Immunocore Holdings plc (NASDAQ:IMCR). The firm noted that positive results from the trials have the potential to boost the stock 25% to 50% and add $300 million to $400 million in annual sales.
Two upcoming trials for the company include second-line Kimmtrak in metastatic cutaneous melanoma (TEBE-AM trial) with data expected by late 2026 or early 2027, and first-line PRAME, for which data is expected in late 2027 or 2028.
Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company that develops TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune conditions. Using its proprietary ImmTAX technology, the company designs therapies that harness the immune system by either activating it to destroy diseased cells or dampening it to reduce autoimmune responses.
5. Qfin Holdings, Inc. (NASDAQ:QFIN)
Market Cap: $1.85 billion
Upside: 90.04%
Number of Hedge Fund Holders: 28
Qfin Holdings, Inc. (NASDAQ:QFIN) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 28, Richard Xu from Morgan Stanley reiterated a Buy rating on the stock with a $50 price target.
Analyst Xu of Morgan Stanley noted that he sees a mix of potential headwinds and competitive strengths for the company, with the positive factors outweighing the negative ones. Some of the headwinds identified by the analyst include new rules in microloans, which will cap yields at 12% and are expected to squeeze the company’s take rate. Xu elaborated that this hits harder for high-yield on-balance-sheet loans shifting to lower-margin models. The analyst noted that the estimated impact on earnings from this rule will be manageable; however, the take rate could decline.
However, on the bright side, Xu noted that China has over 4,800 micro-loan firms. Many of these firms are weak and expected to falter under this new rule. In this situation, Qfin Holdings, Inc. (NASDAQ:QFIN) stands out with cheap funding, allowing it to offer loans below 12% yield, and capturing market share under tough market scenarios.
Qfin Holdings, Inc. (NASDAQ:QFIN) operates as a holding company focused on credit technology services in China. It leverages AI and data analytics to connect borrowers—mainly consumers and small enterprises—with financial institutions.
4. Ardelyx, Inc. (NASDAQ:ARDX)
Market Cap: $1.92 billion
Upside: 60.88%
Number of Hedge Fund Holders: 30
Ardelyx, Inc. (NASDAQ:ARDX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Dennis Ding from Jefferies reiterated a Buy rating on the stock and raised the price target from $8 to $15. Earlier, on January 9, Julian Harrison from BTIG reiterated a Buy rating on Ardelyx, Inc. (NASDAQ:ARDX) and raised the price target from $14 to $17.
Analysts from BITG noted that the positive sentiment is based on the company’s Ibsrela revenue, which grew 73% year-over-year to $274 million in fiscal 2025 and 10% quarter-over-quarter in Q4 2025 to $87 million.
Notably, the company projects fiscal 2026 Ibsrela revenue between $410 million and $430 million, indicating 50% to 58% year-over-year growth. Peak sales are expected to exceed $1 billion in 2029. BTIG noted that the company ended fiscal 2025 with $265 million in cash. The firm believes that Ardelyx, Inc. (NASDAQ:ARDX) has a robust commercial portfolio and a strong pipeline.
Similarly, Citi analyst Yigal Nochomovitz on January 8 also raised the price target from $11 to $14, with a Buy rating. The analyst noted that the management’s expectation to reach $1 billion by 2029 exceeds Citi’s estimates, hence the price target update.
Ardelyx Inc. (NASDAQ:ARDX) discovers, develops, and commercializes medicines to treat unmet medical needs internationally. It offers IBSRELA, which is a minimally absorbed small molecule therapy for patients with IBS with constipation. It also offers XPHOZAH, which is a phosphate absorption inhibitor for adults with chronic kidney disease on dialysis.
3. Extreme Networks, Inc. (NASDAQ:EXTR)
Market Cap: $1.97 billion
Upside: 66.10%
Number of Hedge Fund Holders: 38
Extreme Networks, Inc. (NASDAQ:EXTR) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 28, Extreme Networks, Inc. (NASDAQ:EXTR) reported results for its fiscal Q2 2026. The company grew its quarterly revenue by 14% year-over-year to $317.9 million. The non-GAAP EPS of $0.26 also came in ahead of the $0.21 EPS last year.
Management noted that the fiscal Q2 2026 marked the seventh consecutive quarter of sequential growth. The quarterly revenue was driven by a 25.5% year-over-year increase in Product revenue and 13% increase in Subscription and Support revenue. Notably, the SaaS ARR reached $226.8 million. Management noted that Extreme Networks, Inc. (NASDAQ:EXTR) is taking market share from the largest players in the enterprise networking segment.
Looking ahead, Extreme Networks, Inc. (NASDAQ:EXTR) expects fiscal Q3 2026 revenue in the range of $309.1 million to $314.1 million, with gross margins in the range of 60.4% to 60.8%.
Extreme Networks, Inc. (NASDAQ:EXTR) operates as a developer, marketer, and seller of network infrastructure equipment and related software. It provides ExtremeCloud IQ, ExtremeCloud IQ-Site Engine, and ExtremeCloud IQ Essentials. The company serves mid-market and enterprise customers, as well as service providers across several industries.
2. Nuvation Bio Inc. (NYSE:NUVB)
Market Cap: $1.93 billion
Upside: 105.72%
Number of Hedge Fund Holders: 39
Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 27, Gregory Renza from Turist Financial reiterated a Buy rating on the stock and raised the price target from $11 to $13. Earlier on January 23, Soumit Roy from JonesTrading assigned a Buy rating on Nuvation Bio Inc. (NYSE:NUVB) with a $12 price target.
Analysts from Truist Financial noted that the increase in price target is based on the company’s Q4 2025 pre-report and the firm’s meeting with the company’s management. The firm noted that the company’s Ibtrozi franchise demonstrated a robust opportunity and presents a stronger-than-expected upside. This comes despite seasonal headwinds, which, according to Truist, position the drug as the ROS1 agent of choice.
Moreover, Truist also likes the company’s mIDH1 glioma opportunity as it awaits clarity on registrational timelines. The firm noted that the key study readouts could arrive as early as 2026, adding to the bullish outlook.
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology patients. Its lead asset, IBTROZI (taletrectinib), targets rare and difficult-to-treat cancers. The company emphasizes precision medicine, pipeline expansion, and improving outcomes for patients with limited therapeutic options in oncology.
1. Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Market Cap: $1.97 billion
Upside: 61.64%
Number of Hedge Fund Holders: 40
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock with a $31 price target. Earlier, on January 14, BTIG reiterated a Buy rating on the stock with a $30 price target.
Analysts at BTIG noted that the bullish sentiment follows the company’s recently highlighted key 2026 objectives. Management highlighted that their bexdeg, which is a BTK degrader for relapsed chronic lymphocytic leukemia, is progressing as planned. Moreover, the phase 3 study is expected to feature a head-to-head comparison against Pirtobrutinib, the newest approved BTK inhibitor. The study will prove superiority and match emerging care standards.
In addition, Nurix Therapeutics, Inc. (NASDAQ:NRIX) is also advancing its immunology assets, with Phase 1 data for the Gilead-partnered IRAK4 degrader due in 2026. The firm highlighted that the company holds $664 million in cash, which is sufficient to fund operations into 2028.
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes innovative small molecules and antibody therapies as a novel treatment approach for inflammatory conditions, cancer, and other challenging diseases.
While we acknowledge the potential of NRIX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NRIX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
